Personalized Medicine events

June 2016

International Congress on Personalized Health Care
June 12-15, 2016
Montreal, QC

The aim of this world première is to bring together more than 1000 specialists, researchers, academics, clinicians, managers, economists, representatives of patient associations, ethicists and experts from the pharmaceutical, biotechnology, information and communication technology (ICT) in health and medical technology fields in order to share ideas and pool resources with regards to the development of personalized medicine.

October 2015

Drug, Sex and Genes Workshop
This conference was co-organized by the CIHR Institute of Cancer Research, the CIHR Institute of Gender and Health, and the CIHR Institute of Genetics. Our goal is to impact patient outcomes by better understanding sex-drug-gene interactions and their related health consequences. The Sex, Drugs and Genes Conference provided an opportunity to open a dialogue to inform the development of pharmacogenomics activities (e.g. research funding, platforms development, implementation facilitators) with key stakeholders, including members of academia, the healthcare sector, regulators and industry.

The three main objectives of this conference supporting our desired outcome are:

  • To identify key issues faced in the implementation of mature pharmacogenomics approaches, including target drugs and populations, as well as systems and healthcare processes.
  • To develop a comprehensive view of the Canadian pharmacogenomics landscape;
  • To identify key research investment areas.

The full report is available on the event website.

November 2013

Toward a coordinate approach to care of orphan genetic diseases
Roundtable of the Canadian Institutes of Health Research

An orphan disease is defined as a disease, usually genetic, affecting less than one in 2000 individuals. The prevalence of each varies according to countries and regions. Some of the genetic orphan diseases became a public health issue because of their high regional prevalence.

This roundtable initiated by the CIHR Institute of Genetics, will include representatives of several organizations such as the Université du Québec à Chicoutimi, the McGill University, the Université de Sherbrooke, the Centre de santé et de services sociaux (CSSS) of Chicoutimi and Jonquière, the RQMO, the Corporation de recherche et d’action sur les maladies héréditaires (CORAMH), the Fondation du grand défi Pierre Lavoie and the ÉCOBES group. Following brief presentations from the various participants, proposals will be discussed to highlight what could be the priorities for the development of an integrated strategy of care for orphan diseases in Canada. This roundtable will also allow participants of different regions of Québec to exchange information about this issue as well as allow the CIHR to better identify priority issues for research on orphan diseases.

May 2013

EuroBioForum 2013
May 27-28, 2013
Munich, Germany

This edition of EuroBioForum was held in Munich, Germany May 27-28, 2013 and explored the potential areas for transnational and transregional collaboration in personalized medicine. The Annual Meeting served as a forum for exchanging views on the state of affairs in policy development and deployment, and on the challenges with respect to policies, implementation strategies and required investments. The Conference objectives are to provide insights into current policies, funding mechanisms and research agendas in personalized medicines. Representatives of national and regional governments, bioclusters, regional development agencies, funding agencies, national research councils, learned societies and industrial federations, have attended the meeting. A strong Canadian contribution has been provided through the national perspective presented by CIHR and Genome Canada, and through the regional perspectives of Genome BC, Genome Québec and the Ontario Genomics Institute.

February 2013

Café Scientifique: "Rare or Common? The Role of Genes in Disease"
February 26, 2013
Toronto, ON

This Café allowed deepening the knowledge about our genetic background, and bridging the perceived gap between rare and common diseases.

Date modified: